Evidence map›Paper›PMID 41449573›Full record

ArticleJapanese journal of clinical oncology2026

Nationwide analysis of olfactory neuroblastoma in Japan: evolving treatment approaches and prognostic outcomes.

Mariko Sekimizu, Takuya Mikoshiba, Ryoto Nagai, Naoaki Ishikawa, Takashi Okada, Megumi Kitayama, Daisuke Kawakita, Ken-Ichi Nibu, Seiichi Yoshimoto, Hiroyuki Ozawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Japanese journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mariko SekimizuDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.ORCID 0000-0002-1430-991X
Takuya MikoshibaDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Ryoto NagaiDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Naoaki IshikawaDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Takashi OkadaDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Megumi KitayamaData Center Department, Clinical Study Support Center, Wakayama Medical University Hospital, 811-1 Kimiidera, Wakayama-shi, Wakayama 641-8510, Japan.
Daisuke KawakitaJapan Society for Head and Neck Cancer, 2-4-11 Fukagawa, Koto-ku, Tokyo 135-0033, Japan.ORCID 0000-0003-3794-2790
Ken-Ichi NibuJapan Society for Head and Neck Cancer, 2-4-11 Fukagawa, Koto-ku, Tokyo 135-0033, Japan.
Seiichi YoshimotoJapan Society for Head and Neck Cancer, 2-4-11 Fukagawa, Koto-ku, Tokyo 135-0033, Japan.ORCID 0000-0001-9270-095X
Hiroyuki OzawaDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

Funding

JSPS 24K18554
6 · The paper itself

Abstract

backgroundOlfactory neuroblastoma (ONB) is a rare malignant tumor of the nasal cavity and paranasal sinuses. In this study, we aimed to analyze ONB cases registered in the nationwide Head and Neck Cancer Registry of Japan.

methodsAmong 90 885 head and neck cancer registrations (2011-19), we identified 346 patients with ONB. We summarized demographics, tumor-node-metastasis (TNM) classification, and treatment modalities (surgery, radiotherapy, chemotherapy) and compared patterns between an early (2011-15) and a late (2016-19) period. Survival was analyzed in 95 patients with standardized 5-year outcomes available.

resultsT4 lesions were frequent, and 234 patients (67.6%) received surgery-based treatment, typically combined with postoperative radiotherapy. Over time, endoscopic approaches increased markedly and became predominant over open skull base surgery. Among the 95 patients with evaluable follow-up, the 5-year overall survival (OS) and 5-year recurrence-free survival (RFS) were 85.1% and 62.7%, respectively. Patients <60 years old and female patients exhibited better OS compared to younger patients and males. Postoperative radiotherapy was associated with improved RFS but not OS. Chemotherapy was used more often with open skull base surgery than with other surgical approaches.

conclusionsEndoscopic surgery for ONB rose substantially, while younger age and female sex were associated with better OS, and postoperative radiotherapy was correlated with improved RFS.

Indexed as

Esthesioneuroblastoma, OlfactoryNasal CavityNose NeoplasmsAdolescentAdultAgedAged, 80 and overCombined Modality TherapyFemaleHumansJapanMaleMiddle AgedPrognosisSurvival RateTreatment Outcomeendoscopic surgerynationwide registryolfactory neuroblastomaradiotherapyrecurrence-free survival

Identifiers

PMID41449573
PMCPMC13017732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.